Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma

Paul A. Hamlin, MD
Published: Wednesday, Jun 28, 2017



Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

The interim results of a study of cerdulatinib in non-Hodgkin lymphoma showed partial responses (PRs) in most of the cohorts. The CLL/small lymphocytic leukemia population saw the highest rate activity with 67% of patients achieving a PR.

Additionally, a complete response was seen in the first patient with relapsed/refractory peripheral T-cell lymphoma to be enrolled on the study.
 
SELECTED
LANGUAGE


Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

The interim results of a study of cerdulatinib in non-Hodgkin lymphoma showed partial responses (PRs) in most of the cohorts. The CLL/small lymphocytic leukemia population saw the highest rate activity with 67% of patients achieving a PR.

Additionally, a complete response was seen in the first patient with relapsed/refractory peripheral T-cell lymphoma to be enrolled on the study.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x